Among the mechanisms causing calcific aortic valve disease (CAVD) are mitochondrial dysfunction and immune cell infiltration, but it is not well understood just how they impact CAVD pathogenesis.
Researchers from Huazhong University of Science and Technology and collaborators published results from a study that aimed to assess the potential role of caveolin 3 (CAV3) in mitochondrial function during diabetic cardiomyopathy (DCM).
Reprogramming techniques to generate functional neurons could improve neurodegeneration in the future. A group of researchers from the Institute for Stem Cell Research (ISF) in Germany have found the pathways that play a role in improving the conversion of astrocytes into neurons.
An international team of researchers have developed a new blood test that could detect Parkinson’s disease earlier than current methods. The test, a real-time PCR-based assay, called Mito Dnadx, uses blood to identify damage to mitochondrial DNA (mtDNA) caused by the neurodegenerative condition. Based on the findings published in the journal Science Translational Medicine, the test could allow rapid, noninvasive and accurate identification of Parkinson’s disease (PD) before it causes much damage to the nervous system.
How severe a viral infection is depends on how much the virus is replicating, damaging cells as it does so, and on the response of the immune system. Or so one would think. “Some of the most severe cases of COVID-19 are happening in the absence of replicating virus,” Joseph Guarnieri told BioWorld. In work published in Science Translational Medicine on Aug. 9, 2023, Guarnieri and his colleagues have described how those severe cases unfold, even as there is no replicating virus to be found.
RNA editing in schizophrenia (SCZ)-associated genes was decreased in postmortem brains of individuals of European descent, according to a study from the University of California, Los Angeles (UCLA). The scientists obtained the RNA editome from SCZ brains to detect the sequence changes in their RNA and observed hypoediting in noncoding regions related to mitochondrial function, such as the mitofusin-1 (MFN1) gene.
Unicycive Therapeutics Inc. has announced key efficacy findings with UNI-494 in animal models of geographic atrophy (GA). UNI-494 is a mitochondrial potassium channel (mitoKATP) activator in development for treating diseases affected by mitochondrial dysfunction, such as kidney, liver and ocular diseases.
Pretzel Therapeutics Inc. has launched with a $72.5 million series A financing to pioneer novel therapies to modulate mitochondrial function to treat rare genetic diseases and common diseases of aging.
Minovia Therapeutics Ltd. will collaborate with Astellas Pharma Inc. to research, develop and commercialize cell therapy programs for treating diseases brought on by mitochondrial dysfunction. The candidates will come from Astellas’ genetically engineered, induced pluripotent stem cells. Haifa, Israel-based Minovia will receive $20 million in cash up front.
Minovia Therapeutics Ltd. will collaborate with Astellas Pharma Inc. to research, develop and commercialize cell therapy programs for treating diseases brought on by mitochondrial dysfunction. The candidates will come from Astellas’ genetically engineered, induced pluripotent stem cells. Haifa, Israel-based Minovia will receive $20 million in cash up front.
